Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a late-stage biopharmaceutical company focused on central nervous system (CNS), inflammatory, and cardiometabolic diseases. The RVPH news feed highlights the company’s progress in advancing its pipeline, particularly its lead candidate brilaroxazine (RP5063), which is being developed for schizophrenia and explored for additional indications such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).
News updates commonly cover clinical trial milestones, including data from the Phase 3 RECOVER program in schizophrenia and its 1-year open-label extension. Reviva has reported broad-spectrum efficacy across major symptom domains, reductions in proinflammatory cytokines, and long-term safety and tolerability data for brilaroxazine. The company also releases information on biomarker research, such as vocal biomarker analyses that use speech latency to characterize negative symptoms and enrich antipsychotic clinical trials.
Regulatory and corporate developments are another key theme in RVPH news. Investors can follow announcements related to FDA interactions, including pre-New Drug Application (pre-NDA) feedback recommending a second Phase 3 trial in schizophrenia, as well as plans for the RECOVER-2 registrational study, subject to financing. Updates on Orphan Drug Designation for PAH and IPF, European patent grants for pulmonary fibrosis, and broader intellectual property strategy are also featured.
In addition, the news flow includes participation in scientific meetings, investor conferences, and key opinion leader events, where Reviva presents clinical and mechanistic data on brilaroxazine. For market participants tracking RVPH stock, this page consolidates company-issued press releases on clinical data, regulatory guidance, financing transactions, and strategic presentations in one place.
Reviva Pharmaceuticals (NASDAQ: RVPH) will present new data on the anti-inflammatory effects of brilaroxazine at Neuroscience 2025 in San Diego.
The late-breaker poster (Session A.10, LBP010) on Nov 15, 2025, 1:00–5:00 PM PT covers RECOVER Phase 3 double-blind results in acute schizophrenia and 12-month open-label extension data in clinically stable patients, focusing on BDNF and inflammatory cytokines. Abstracts and poster details are available on the Neuroscience 2025 website.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that European Patent 3749324 was granted by the EPO on Nov 10, 2025, covering use of brilaroxazine to treat pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF).
The patent adds to existing protection in key markets including the United States, China, and Japan. Brilaroxazine is described as having a novel mechanism that targets disrupted serotonin signaling implicated in pulmonary fibrosis. The drug has received Orphan Drug Designation from the U.S. FDA for IPF. Management said the asset is late-stage and has been well-tolerated across large patient populations, supporting plans to expand clinical development from schizophrenia into additional indications.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, will participate in the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025 in New York City.
The conference will feature more than 60 selected companies, over 500 institutional and high-net-worth investors, main-stage presentations, expert panels, curated one-on-one meetings, and networking sessions designed to connect growth companies with the investment community.
Investors seeking registration or agenda details are directed to the Spartan Capital Investor Conference 2025 registration page.
Reviva (NASDAQ: RVPH) will present data on negative symptoms for brilaroxazine from the Phase 3 RECOVER program at CNS Summit 2025 in Boston.
The presentation covers results from the double‑blind RECOVER trial in acute exacerbation of schizophrenia and the long‑term open‑label extension in clinically stable patients over one year. Poster Number 32 is scheduled for Nov 3 and Nov 4, 2025, 5:00–7:00 PM ET. The conference runs Nov 2–5, 2025. Abstracts and additional details are available on the CNS Summit 2025 website.
Reviva Pharmaceuticals (NASDAQ: RVPH) said CEO Laxminarayan Bhat, PhD, will join a Key Opinion Leader webinar and fireside chat hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET.
The session will include KOLs Dr. Larry Ereshefsky and Dr. Mark Opler, focus on the unmet need and treatment landscape for schizophrenia, and discuss phase 3 clinical data for Reviva’s lead candidate brilaroxazine. The conversation will be moderated by James Molloy of A.G.P. A replay will be posted in Reviva’s investor relations section after the event.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the 4th Annual Roth Healthcare Opportunities Conference on October 9, 2025, in New York.
CEO Laxminarayan Bhat will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" at 8:00 AM ET and will be available for one-on-one meetings with investors throughout the day.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate presentation on Tuesday, September 30, 2025, at 10:15 AM ET.
The virtual event will include a corporate presentation and one-on-one meetings with management. Investors interested in scheduling meetings can contact Lytham Partners directly or register through the conference website.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced the pricing of a $9 million public offering. The offering includes 27 million shares of common stock (or equivalents) along with Series E and F warrants, priced at $0.335 per share and accompanying warrants.
The Series E warrants will expire in 5 years while Series F warrants will expire in 12 months, both with an exercise price of $0.335 per share. The offering is expected to close around September 22, 2025. Proceeds will support research and development activities and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a proposed public offering of common stock and warrants. The offering will include shares of common stock (or equivalents) and warrants to purchase common stock, with A.G.P./Alliance Global Partners serving as the sole placement agent.
The proceeds will be used to fund research and development activities and for working capital purposes. The securities will be offered through an effective shelf registration statement on Form S-3. The completion of the offering is subject to market conditions, with no guaranteed size or terms.
Reviva Pharmaceuticals (NASDAQ: RVPH) has reported significant progress in its brilaroxazine development program for schizophrenia treatment, alongside Q2 2025 financial results. The company successfully completed its Phase 3 RECOVER open-label extension (OLE) 1-year study, demonstrating sustained efficacy across all symptom domains and a well-tolerated safety profile.
Key clinical achievements include robust broad-spectrum efficacy with improvements in PANSS total score (-18.1), positive symptoms (-5.0), and negative symptoms (-4.4). The company plans to meet with the FDA in Q4 2025 to discuss the path to approval, with a potential NDA submission targeted for Q2 2026.
Financially, Reviva reported a net loss of $6.1 million ($0.12 per share) for Q2 2025, compared to $7.9 million in Q2 2024. The company's cash position stands at $10.4 million, bolstered by a recent $10.0 million public equity offering.